Adaptive Biotechnologies (NASDAQ: ADPT) COO sells shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and related stock sales. She exercised options to acquire 44,166 shares of common stock at exercise prices of $7.27 and $8.46 per share, then sold 57,180 shares in open-market transactions at weighted average prices generally in the mid‑teens per share. These trades, executed on April 9, 10, and 13, were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. After the transactions, Rubinstein directly owned 421,174 shares of Adaptive Biotechnologies common stock.

Insider Trade Summary 10b5-1

Net Seller: 57,180 shares ($758,108)

Net Sell 14 txns

Insider RUBINSTEIN JULIE

Role President and COO

Sold 57,180 shs ($758K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	8,109	$0.00	--
Exercise	Stock Option (right to buy)	6,613	$0.00	--
Exercise	Common Stock	8,109	$7.27	$59K
Exercise	Common Stock	6,613	$8.46	$56K
Sale	Common Stock	15,722	$12.95	$204K
Sale	Common Stock	3,338	$14.08	$47K
Exercise	Stock Option (right to buy)	14,722	$0.00	--
Exercise	Common Stock	14,722	$7.27	$107K
Sale	Common Stock	18,660	$12.75	$238K
Sale	Common Stock	400	$13.48	$5K
Exercise	Stock Option (right to buy)	14,722	$0.00	--
Exercise	Common Stock	14,722	$7.27	$107K
Sale	Common Stock	16,960	$13.79	$234K
Sale	Common Stock	2,100	$14.44	$30K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 433,621 shares (Direct)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $13.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.87 to $14.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option is fully vested and exercisable. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Key Figures

Shares sold: 57,180 shares Options exercised: 44,166 shares Exercise prices: $7.27 and $8.46 per share +4 more

7 metrics

Shares sold 57,180 shares Total open-market sales of common stock reported

Options exercised 44,166 shares Total underlying common shares from option exercises

Exercise prices $7.27 and $8.46 per share Exercise or conversion prices for stock options

Holdings after trades 421,174 shares Common stock directly owned after all transactions

Sale prices $12.75–$14.44 per share Representative reported weighted average sale prices

10b5-1 plan adoption date November 18, 2025 Date the pre-arranged trading plan was adopted

Net share direction Net sell of 57,180 shares transactionSummary netBuySellShares and netBuySellDirection

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

""security_title": "Stock Option (right to buy)""

weighted average price financial

"The price reported for this transaction is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

""transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

""transaction_action": "derivative exercise/conversion""

Form 4 Insider Transactions: What Each Field Means →

04/13/2026 - 07:44 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/09/2026		M⁽¹⁾		14,722	A	$7.27	448,910	D
Common Stock	04/09/2026		S⁽¹⁾		16,960	D	$13.79⁽²⁾	431,950	D
Common Stock	04/09/2026		S⁽¹⁾		2,100	D	$14.44⁽³⁾	429,850	D
Common Stock	04/10/2026		M⁽¹⁾		14,722	A	$7.27	444,572	D
Common Stock	04/10/2026		S⁽¹⁾		18,660	D	$12.75⁽⁴⁾	425,912	D
Common Stock	04/10/2026		S⁽¹⁾		400	D	$13.48⁽⁵⁾	425,512	D
Common Stock	04/13/2026		M⁽¹⁾		8,109	A	$7.27	433,621	D
Common Stock	04/13/2026		M⁽¹⁾		6,613	A	$8.46	440,234	D
Common Stock	04/13/2026		S⁽¹⁾		15,722	D	$12.95⁽⁶⁾	424,512	D
Common Stock	04/13/2026		S⁽¹⁾		3,338	D	$14.08⁽⁷⁾	421,174	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.27	04/09/2026		M⁽¹⁾			14,722	⁽⁸⁾	02/07/2029	Common Stock	14,722	$0	22,831	D
Stock Option (right to buy)	$7.27	04/10/2026		M⁽¹⁾			14,722	⁽⁸⁾	02/07/2029	Common Stock	14,722	$0	8,109	D
Stock Option (right to buy)	$7.27	04/13/2026		M⁽¹⁾			8,109	⁽⁸⁾	02/07/2029	Common Stock	8,109	$0	0	D
Stock Option (right to buy)	$8.46	04/13/2026		M⁽¹⁾			6,613	⁽⁹⁾	03/06/2033	Common Stock	6,613	$0	192,936	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $13.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

6. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

7. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.87 to $14.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

8. The option is fully vested and exercisable.

9. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Adaptive Biotechnologies (ADPT) executive Julie Rubinstein report in this Form 4?

Julie Rubinstein reported a mix of option exercises and share sales. She exercised stock options for 44,166 Adaptive Biotechnologies shares and sold 57,180 shares in open-market transactions, ending with 421,174 shares owned directly after these trades.

How many Adaptive Biotechnologies (ADPT) shares did Julie Rubinstein sell and at what prices?

Julie Rubinstein sold 57,180 Adaptive Biotechnologies common shares. The reported sales occurred at weighted average prices including $12.75, $13.48, $13.79, $14.44, $12.95, and $14.08 per share, with detailed price ranges described in the Form 4 footnotes.

How many Adaptive Biotechnologies (ADPT) options did Julie Rubinstein exercise in this filing?

She exercised stock options covering 44,166 shares of Adaptive Biotechnologies common stock. The options had exercise prices of $7.27 and $8.46 per share, converting derivative positions into directly owned shares before related open-market sales were executed.

How many Adaptive Biotechnologies (ADPT) shares does Julie Rubinstein hold after the transactions?

Following the reported transactions, Julie Rubinstein directly owns 421,174 Adaptive Biotechnologies common shares. This figure reflects her position after exercising stock options and selling 57,180 shares over several days of trading activity disclosed in the Form 4.

Were Julie Rubinstein’s Adaptive Biotechnologies (ADPT) trades made under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that these transactions were effected pursuant to a Rule 10b5-1 trading plan. The plan was adopted on November 18, 2025, indicating the sales were pre-arranged rather than timed opportunistically by the executive.

What types of securities are involved in Julie Rubinstein’s Adaptive Biotechnologies (ADPT) Form 4?

The filing covers stock options and common stock. Rubinstein exercised stock options described as “Stock Option (right to buy)” into common shares, then sold portions of that common stock in open-market transactions at various weighted average prices.